Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BRC Doses First Patient in Cannabinoid Therapy Study for Complex Regional Pain Syndrome
Details : BRC-002 (cannabidiol) is a first-in-class therapeutic product candidate aiming to address pain and co-morbidities of Complex Regional Pain Syndrome.
Brand Name : BRC-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Recipient : Open Book Extracts
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The partnership with BRC, supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9-tetrahydrocannabinol.
Brand Name : Delta-9 THC
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2022
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : Open Book Extracts
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
